Information  X 
Enter a valid email address

MaxCyte books annual loss owing to R&D, marketing spending

By BFN News | 07:52 AM | Wednesday 24 April, 2019


Cell-based medicines group MaxCyte booked a full-year loss after rising sales were more than offset by spending, including on R&D and marketing. Net losses for the year through December amounted to $8.9m, compared to losses of $9.9m on-year. Revenue rose 19% to $16.7m. 'Our core markets, cell therapy and immuno-oncology, continue to expand rapidly as do applications for gene-editing technologies in the development of various therapies for the treatment of inherited genetic diseases and a number of cancers,' chief executive Doug Doerfler said. 'Our unique technology places MaxCyte at the forefront of a wide variety of programmes with leading global partners across this exciting and increasingly valuable area of healthcare.' Story provided by StockMarketWire.com

a d v e r t i s e m e n t